
    
      The study has 2 study arms:

        -  Nivolumab alone (Arm A)

             -  Induction phase: nivolumab 3 mg/kg IV infusion every 2 weeks x3 doses. Followed by
                Definitive Surgery.

             -  Maintenance phase: nivolumab 3 mg/kg IV infusion every 3 weeks for up to one year
                from study treatment initiation.

        -  Ipilimumab + nivolumab (Arm B)

             -  Induction phase: Ipilimumab 3 mg/kg IV + Nivolumab 1 mg/kg IV every 3 weeks x2.
                Followed by Definitive Surgery.

             -  Maintenance phase: nivolumab 3 mg/kg IV infusion every 2 weeks for up to one year
                from study treatment initiation.

      Definitive Surgery consists of complete lymph node dissection/ lymphatic, cutaneous,
      subcutaneous or other distant disease resection (week 6-8+).
    
  